Anttila S, Huuhka K, Huuhka M, Rontu R, Mattila K M, Leinonen E, Lehtimäki T
Medical School, University of Tampere, Tampere, Finland.
J Neural Transm (Vienna). 2007;114(4):461-8. doi: 10.1007/s00702-006-0583-6. Epub 2006 Oct 27.
We studied the association between tryptophan hydroxylase 1 (TPH1) A218C and G-protein beta-3 subunit (GNB3) C825T polymorphisms and treatment response in electroconvulsive therapy (ECT). The sample consisted of 119 patients with major depressive disorder (MDD) and 398 controls. Neither TPH1 nor GNB3 polymorphisms are associated with treatment response. However, subjects carrying TPH1 CC genotype are more likely to belong to the patient sample than to the controls. In female subjects, T-allele of GNB3 polymorphism increases the risk of being a treatment-resistant patient with MDD. Moreover, in females the combination of TPH1 CC and GNB3 CT + TT genotype is associated with an increased risk of belonging to the patient group.
我们研究了色氨酸羟化酶1（TPH1）A218C和G蛋白β3亚基（GNB3）C825T基因多态性与电休克治疗（ECT）疗效之间的关联。样本包括119例重度抑郁症（MDD）患者和398名对照。TPH1和GNB3基因多态性均与治疗反应无关。然而，携带TPH1 CC基因型的受试者相较于对照组更有可能属于患者样本。在女性受试者中，GNB3基因多态性的T等位基因增加了成为难治性MDD患者的风险。此外，在女性中，TPH1 CC与GNB3 CT + TT基因型的组合与属于患者组的风险增加相关。
